Ucb Pharma, S.a.

Ucbbiopharma Srl

Ucb Biopharma Sprl

Mark Ellis

David Paul Humphreys

Kerry Louise Tyson

Daniel John Lightwood

Lara Kevorkian

Diane Marshall

Carl Brendan Doyle

Joanne Elizabeth Compson

Andrew Charles Payne

Alison Turner

Kate Louise Dixon

Maria Margarida Gouveia Sancho

Raymond Anthony Jupp

Joseph Michael David Rastrick

Helene Bon

Monika-Sarah Schulze

Laura Ellen Newnham

The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.

Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis

The present invention provides a recombinant gram-negative bacterial cell comprising an expression vector comprising a recombinant polynucleotide encoding DsbC and one or more polynucleotides encoding an antibody or an antigen-binding fragment thereof specifically binding to CD154.

Bacterial host strain expressing recombinant DSBC

The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, 170, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell.

Bacterial host strain comprising a mutant spr gene and having reduced Tsp activity

A recombinant gram-negative bacterial cell comprising one or more of the following mutated protease genes: a) a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having reduced protease activity or is a knockout mutated Tsp gene; b) a mutated ptr gene, wherein the mutated ptr gene encodes a Protease III protein having reduced protease activity or is a knockout mutated ptr gene; and c) a mutated DegP gene encoding a DegP protein having chaperone activity and reduced protease activity; wherein the cell is isogenic to a wild-type bacterial cell except for the mutated Tsp gene and/or mutated ptr gene and/or mutated DegP gene and optionally a polynucleotide sequence encoding a protein of interest.

Bacterial host strain

The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a mutant spr protein and wherein the cell comprises a non-recombinant wild-type chromosomal Tsp gene.

Bacterial host strain comprising a mutant SPR gene and a wild-type TSP gene

The present invention provides a recombinant gram-negative bacterial cell, characterized in that the cell comprises a recombinant polynucleotide encoding DsbC and has reduced Tsp protein activity compared to a wild-type cell.

Bacterial host strain expressing recombinant DsbC and having reduced Tsp activity

The invention relates to a transcriptionally active recombinant linear polynucleotide encoding a multimeric protein comprising in the following order, a first promoter sequence, a first encoding polynucleotide sequence, a bidirectional regulatory sequence, a second encoding polynucleotide sequence and a second promoter sequence, wherein the first and second encoding polynucleotide sequences are in convergent transcriptional orientation, each encoding polynucleotide sequence encodes a component of the multimeric protein and the bidirectional regulatory sequence is operably linked to the first and second encoding polynucleotide sequences and the multimeric protein is an antibody or fragment thereof and each encoding polynucleotide sequence encodes one or more antibody domains or fragments thereof.

Method for producing proteins

The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell.

Bacterial host strain comprising a mutant SPR gene and having reduced TSP activity

Bacterial host strain comprising a mutant spr gene and a wild-type Tsp gene

The present invention provides a dicistronic message for producing an antibody molecule, in which the upstream cistron contains DNA coding for the light chain of the antibody and the downstream cistron contains DNA coding for the corresponding heavy chain, characterised in that the dicistronic message comprises a sequence selected from AEOS1 (SEQ ID NO:1), AEOS2 (SEQ ID NO:2), AEOS3 (SEQ ID NO:3), AEOS4 (SEQ ID NO: 4), AEOS5 (SEQ ID NO:5), AEOS6 (SEQ ID NO:6), AEOS7 (SEQ ID NO:7), AEOS8 (SEQ ID NO:8), AEOS9 (SEQ ID NO:9), AEOS1O (SEQ ID NO:10) and AEOS11 (SEQ ID NO:11).

Growing community of inventors

Slough, United Kingdom

Mark Ellis